Agilon Health (AGL) Q2 2026 Earnings Call Transcript
Agilon Health (AGL) reported Q2 2026 revenue of $1.49B, up 7% y/y, and adjusted EBITDA of $70M, above guidance, citing favorable medical cost development and higher risk adjustment revenue. FY2026 guidance was raised to $5.78B-$5.86B revenue and $75M-$95M adjusted EBITDA. Medicare Advantage membership fell to 437k. Cash and marketable securities were $257M at June 30, 2026.
How this was made
The 30-second read
Why it matters
The key tradable change is the substantial upward revision to FY 2026 adjusted EBITDA guidance, supported by improved medical margin and a lower medical cost trend, while management flags potential volatility from reserving and limited paid-claims visibility.
Market read
Traders can update models around FY 2026 profitability and medical cost trajectory after the guidance raise, while monitoring membership trends and reserving-related volatility.
What to watch
Medicare Advantage membership declined 12% YoY, and management highlighted reserving based on limited paid claims, both of which can pressure future quarters even with higher full-year guidance.
Background
Agilon Health is a Medicare Advantage-focused provider operating under CMS risk adjustment and ACO-related programs; this transcript covers Q2 results and FY 2026 outlook updates.
Ticker impact
Agilon reported Q2 2026 revenue of $1.49B and raised FY 2026 adjusted EBITDA guidance to $75M-$95M on improved medical margin and risk adjustment.
Likely positive bias for near-term trading as guidance is materially upgraded, tempered by commentary on reserving-driven volatility.
The article discloses multiple fresh, company-specific guidance revisions (revenue and especially adjusted EBITDA) plus Q2 medical margin improvement and a low-7% cost trend, which typically supports re-rating despite stated near-term reporting uncertainty.
Market effects
Signals improving execution in Medicare Advantage risk adjustment and medical cost management, relevant to managed care peers watching similar cost trend dynamics.
No specific regional impact disclosed.
Primarily US Medicare Advantage and CMS model dynamics; limited global spillover mentioned.
Counterpoint
The company attributes outperformance to favorable medical expense development and revised risk scores, which may not fully persist if paid-claims data later reverses.
Key entities
- companyAgilon Health, Inc.
Reported Q2 2026 results and materially raised FY 2026 adjusted EBITDA guidance, citing improved medical margin and risk adjustment revenue.
- executiveTimothy O’Rourke
CEO who discussed clinical pathway progress, AI-enabled operating model, and efforts to reduce physician and group variability.
- executiveJeffrey Schwaneke
CFO who discussed low-7% medical cost trend and reserving approach, plus Part D exposure risk management.
